Pancreatic Cancer Research

ResearcherNanjing Medical UniversityActive in the last 2 years

Shangshang Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-3828-9907; OpenAlex author ID A5006447099, A5101576394. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Co-author DOI 10.1038/s41419-024-06425-y↗
  2. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Co-author DOI 10.3892/or.2012.1729↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jia Ma · 1 shared paper, 2024 · strength 0.19
  2. Jun Xia · 1 shared paper, 2024 · strength 0.19
  3. Kai Chen · 1 shared paper, 2024 · strength 0.19
  4. Zhiwei Peter Wang · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.